Signaling architecture of the glucagon-like peptide-1 receptor
Human Case Reports and Practitioner Feedback Although randomized trials are pending, case reports and practitioner feedback are encouraging
Environ Sci Pollut Res
On phentermine, the stimulant effect may actually increase exercise capacity and motivation, though patients should monitor heart rate carefully during workouts
Orforglipron (LY3502970), a novel, oral nonpeptide glucagonlike peptide1 receptor agonist: a Phase 1a, blinded, placebocontrolled, randomized, singleand multipleascendingdose study in healthy participants
CCM identifies nerve damage before symptoms or electrophysiological abnormalities appear [45, 46]